Drug news
Exelixis reports results for XL 184 in Thyroid Cancer
Top line results were reported by Exelixis for XL 184 (cabozantinib) for the primary endpoint in the 330-patient Phase III EXAM study in patients with locally advanced or metastatic medullary Thyroid Cancer which showed a 7.2-month improvement in progression-free survival (PFS) with cabozantinib compared to placebo - 11.2 months of PFS versus four months. n terms of secondary endpoints, the overall response rate was 28% in the cabozantinib arm and 0% in the placebo arm. The Kaplan Meier estimate for PFS at one year was 47.3% with cabozantinib and only 7.2% for patients on placebo. Overall survival data are not yet mature.
150 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.